Drugs / RSV LID cp ΔM2-2
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02890381 | Oct 2016 → Apr 2017 | respiratory syncytial virus infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | Missed primary |
| Phase 1 | NCT02948127 | Sep 2016 → Apr 2017 | respiratory syncytial virus infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RSV LIDcpΔM2-2 | “RSV LIDcpΔM2-2 is overattenuated.” PMID 31211158 ↗ May 2019 |
| Known as | LIDcpΔM2-2 | “The live respiratory syncytial virus (RSV) candidate vaccine LIDcpΔM2-2 is attenuated through deletion of M2-2 and 5 cold-passage mutations.” PMID 31211158 ↗ May 2019 |
| Modality | Vaccine | “a recombinant live-attenuated RSV vaccine” NCT02890381 ↗ |
| Route | Intranasal | “administered as nose drops” NCT02890381 ↗ |